Infectious Diseases
INFLUENCE OF GLUTARGIN AND ERBISOL COMBINATION ON INDEXES OF PERIPHERAL OXIDATION OF LIPIDS IN WOMEN WITH CHRONIC UROGENITAL CHLAMYDIOSIS
Problemy ekologichnoi i medychnoi genetyky i klinichnoi imunologii: zbirnyk naukovykh prats. – 2003. – Issue 6 (52). – P. 153-159
INFLUENCE OF ERBISOL AND CYCLOFERON ON CLINICO-IMMUNOLOGICAL PARAMETERS IN PATIENTS WITH SEVERE FORM OF EPIDEMIC PAROTITIS
Infektsiyni chvoroby. – 2003. – № 4. – P. 27-30
OPTIMIZATION OF THE APPLICATION SCHEME OF IMMUNOMODULATOR ERBISOL® ULTRAPHARM IN COMPLEX TREATMENT OF PATIENTS WITH CHRONIC PERSISTENT VIRAL INFECTION (REVIEW OF LITERATURE AND ORIGINAL DATA)
Suchasni infektsii. – 2010. – № 2. – P. 128-134
PREPARATIONS OF CLASS ERBISOL® IN THERAPY OF VIRAL INFECTIONS
Sovremennaja pharmatsija. – 2012 / December. – P. 36-43
Viral hepatitis
EXPERIENCE OF ERBISOL TREATMENT OF PATIENTS WITH VIRAL HEPATITIS “B”
Pharmakologichny visnyk. – 1999. – № 5. – P. 54-57
CHARACTERISTICS OF IMMUNOCOMPETENT CELLS PHENOTYPE IN PATIENTS WITH CHRONIC HEPATITIS C IN DYNAMICS OF TREATMENT BY ERBISOL® ULTRAPHARM
Liky. – 2004. – № 5/6. – P. 118-122
DOMESTIC DRUG ERBISOL® ULTRAPHARM IN TREATMENT CHRONIC HEPATITIS C
Suchasni infektsii. – 2005. – № 2. – P. 63-70
A NEW PREPARATION IN TREATMENT OF CHRONIC HEPATITIS C (PART I)
Visnyk pharmakologii ta pharmatsii. – 2005. – № 5. – P. 24-27
A NEW PREPARATION IN TREATMENT OF CHRONIC HEPATITIS C (PART II)
Visnyk pharmakologii ta pharmatsii. – 2005. – № 6. – P. 17-21